THE ONLY SYSTEM^

CLINICALLY PROVEN
TO REDUCE
HYPOGLYCAEMIA

MINIMED 640G system^

with SmartGuard
technology

HCP BROCHURE.v7.indd 1

18/07/2016 2:06 PM

HYPOGLYCAEMIA
IS CHALLENGING
FOR GLYCAEMIC
CONTROL AND
quality of life
1

Achieving good glucose control without the risk or fear of going

low is a challenging balancing act for you and your patients.

74%

ON AVERAGE
A PATIENT
EXPERIENCEs

of type 1

patients report
altering insulin
doses out of fear
of hypoglycaemia.3

SYMPTOMATIC
HYPOS PER WEEK. 1

26%

poor
glycaemic
control

of severe
hypoglycaemic
events lead to

seizures & coma.

HCP BROCHURE.v7.indd 2

Provides risk for

both development and
progression of diabetes
complications.5

18/07/2016 2:06 PM

Patients with severe hypoglycaemia have a greater fear of

hypos, more diabetes-related distress and poorer general
emotional wellbeing.3

38%

of emergency medical
service call outs for
hypoglycaemia result
in hospitalisation.6

Hypoglycaemia is the biggest barrier to good

glycaemic control in patients with type 1 diabetes.
It causes fear and worry for patients and is costly
to our healthcare budgets.
Dr Conget

HCP BROCHURE.v7.indd 3

18/07/2016 2:06 PM

MINIMED 640G system^

WITH SMARTGUARD

PROVIDES ADVANCED
PROTECTION AGAINST
HYPOGLYCAEMIA
7

75%

Of SmartGuard
events did not
hit the low 8
glucose limit.

Based upon SmartGuard real life data from 4,818 patients*

SmartGuard, our exclusive closed loop technology, provides

protection against hypoglycaemia.8 It can:
HELP Prevent severe hypoglycaemic episodes
Automatically stops insulin when sensor glucose is predicted to approach a pre-set low limit.

Help Avoid hyperglycaemic rebound

Resumes insulin delivery when levels recover.

Help provide Better protection against lows

Allows your patients to set multiple low limits throughout the day and night.

HCP BROCHURE.v7.indd 4

18/07/2016 2:06 PM

trust smartguard
to do the work
NO INCREASE IN HYPERGLYCAEMIA

SmartGuard technology provides advanced protection from

hypoglycaemia without significant increase in hyperglycaemia.1

SmartGuard Real Life Performance Data*

SmartGuard feature:
On
O

12.0

Sensor Glucose mmol/L

10.0

High limit

8.0

6.0

4.0

Low limit
2.0

0
-2

-1

Time from the Suspend event (hr)

20

6674891:;<=5>?1@AA1#*1B5/C5>0345

LESS GLYCAEMIC VARIABILITY

300

Sensor Glucose values associated with automatically-resumed

events showed less glycaemic variability than those associated
with manually-resumed events.7

80

250

Glucose mg/dL

200

60

150

Trust our accurate system to provide Advanced Protection

for your patients (9.1% MARD).9

40

100

50

20

* Medtronic data on file: SmartGuard technology real life data evaluated using the voluntary MiniMed0640G system uploads to CareLink Personal from Jan. 13th 2015 to Jan. 14th 2016.
-120

-60

60

120

180

240

300

360

Time from event start (minutes)

With SmartGuard
HCP BROCHURE.v7.indd 5

Without SmartGuard
18/07/2016 2:06 PM

how smartguard works

SmartGuard feature:
On
O

6.7
Insulin suspended

SmartGuard suspends insulin

when sensor glucose is
approaching a pre-set low limit.*

predicted

5.6

Sensor Glucose mmol/L

predicted

SmartGuard resumes basal insulin

Delivery will automatically resume
if sensor glucose recover.**

4.5

Low limit

3.4

2.3
1:00

1:30

2:00

2:30

3:00

3:30

4:00

4:30

Time of day (AM)

The dynamic suspend feature is based on certain criteria: sensor glucose must be within 3.9mmol/L of the low limit and predicted to be 1.1mmol/L above the low limit within 30 minutes
AND the pump must not be in the refractory period. **The dynamic resume feature is based on certain preset criteria: sensor glucose must be 1.1mmol/L above the preset low limit and
predicted to be 2.2mmol/L above within 30 minutes AND insulin must have been suspended for at least 30 minutes.

The MiniMed 640G

system^ with
SmartGuard significantly
reduces hypoglycaemia
in clinical practice and
allows more time to
be spent within target
glycaemic range.

HCP BROCHURE.v7.indd 6

18/07/2016 2:06 PM

MINIMED 640G system^

greater CONVenIENCE
IMPROVED DESIGN
Diabetes is already complicated, your patients
system shouldnt be.

greater Convenience
Greater and easier dosing for patients with the Bolus Wizard calculator.*
Preset bolus options, personalised basal patterns and programmable reminders for easy
customising of your patients therapy.

Improved Design
Intuitive10 navigation for easy training.
Waterproof ** allowing uninterrupted wear.
Full-colour, auto-brightness display for legibility even for patients with reduced eyesight.
* Calculation is based on the amount of insulin currently in the body, the amount of carbohydrates, the users current and target blood sugar levels, their insulin-to-carb
ratio and their bodys sensitivity to insulin. Proper Bolus Wizard setup must be completed first. Users must input the number of carbohydrates their current blood glucose
value before the Bolus Wizard can calculate the insulin users.
** Waterproof at time of manufacture up to 3.6 meters for up to 24 hours at a time. See MiniMed 640G User Guide for a complete description of the waterproof capabilities
and proper use instructions.

HCP BROCHURE.v7.indd 7

18/07/2016 2:06 PM

MINIMED 640G system^ WITH

SMARTGUARD technology

it thinks

insulin delivery

Medtronic offers a wide range

of infusion sets so that you
can choose the right infusion
set for your patients comfort
and safety.

therapy
management tools

CareLinkTM Pro software includes

insightful trend reports and
therapy considerations to help
you make informed treatment
decisions for your patients.

continuous
glucose
monitoring

The Enlite sensor provides

a reliable9 CGM experience for
your patients.1

Blood Glucose Testing

ContourNext LINK 2.4

meter links wirelessly to
MiniMed 640G and provides
proven11,12 testing accuracy
and discreet remote bolusing.

1
Cryer, PE. Diabetologia. 2002, Jul 45(7):937-48. 2 Hendrieckx, C. et al. Diabetes Research and Clinical Practice 2014. 3 Fidler, C. et al. J Med Econ. 201114(5)646-655. 4 DCCT Group. N Engl J Med. 1993 Sep; 329:977986. 5 Skyler, JS. Edocrinol Metab Clin North Am. 1996 Jun; 25(2)243-54. 6 Villani, M. et al. Journal of Diabetes and its Complications. 2016. 7 Choudhary, P. et al. Diabetes Technol. Ther. 2016, Vol 18 (5). 8 Medtronic
data on file: SmartGuard real life data. Medtronic MiniMed evaluated using the voluntary MiniMed 640G uploads to CareLink Personal from Jan. 13th 2015 to Jan. 14th 2016. 9 Cohen, O. et al. Diabetes Technol.
Ther. Feb 2016, 18(S1): A-81-82. 10 CCR Study, 2012 HFMD, Inc. Data on file at Medtronic MiniMed, Inc. Northridge, CA. 11 Bailey, T. et al. Clin Chim Acta 2015 Aug; 448:139-45. 12 In vitro diagnostic test systemsrequirements for blood glucose monitoring systems for self-testing in managing diabetes mellitus. Geneva, Switzerland: International Organization for Standardization; ISO 15197:2013.

When combined with the MiniMed 640G system and Guardian 2 Link transmitter. ^Components sold separately

Medtronic Australasia Pty Ltd,

97 Waterloo Road, North Ryde NSW 2113 Australia
Mail: Medtronic Diabetes, PO Box 945, North Ryde, NSW 1670
24-hour Toll Free: 1800 777 808
australia.diabetes@medtronic.com
Facebook: www.facebook.com/MedtronicDiabetesAUS
Instagram: @MedtronicDiabetesAus
YouTube: Medtronic Diabetes ANZ
https://hcp.medtronic-diabetes.com.au
Safety Information: MiniMed 640G
MiniMed 640G Insulin Pump system is indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. In addition, the pump system is
indicated for continuous or periodic monitoring of glucose levels in the fluid under the skin, and possible low and high glucose episodes. When using a sensor and transmitter, the pump displays continuous glucose
values and stores this data so that it can be analyzed to track patterns and improve diabetes management. Pump history can be downloaded to a computer for analysis of historical glucose values. The continuous
sensor glucose values provided by the MiniMed 640G insulin pump system are not intended to be used directly for making therapy adjustments. Rather, they provide an indication that a confirmation fingerstick
measurement may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not based on the value displayed by the pump. For listings of indications,
contraindications, precautions, warnings and parental adverse events, please refer to the instructions for use. MiniMed 640G, SmartGuard, Bolus Wizard, Guardian 2 CareLink and Enlite are Trademarks of
Medtronic Inc. Bayer, Bayer Cross are trademarks of Bayer. Ascensia and CONTOUR are trademarks of Ascensia Diabetes Holdings AG.
Please visit www.medtronicdiabetes.com/importantsafetyinformation for complete details.

HCP BROCHURE.v7.indd 8

APPROVAL #3105-062016 Date of prep: April 2016

18/07/2016 2:07 PM